Aglaia is an investment fund fully focused on the fight against cancer and the development of improved anti-cancer drugs in particular. Aglaia has a proven ability to select and mature early-stage breakthrough inventions that have the potential to transform cancer treatment.
For more information, please visit www.aglaia-oncology.com
Company Details
- Employees
- 6
- Founded
- -
- Address
- Prof. Bronkhorstlaan 10-92, Bilthoven,3723 Mb,netherlands
- Phone
- +31 30 229 6090
- in****@****cal.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aglaia-biomedical.com
- Keywords
- Utrecht.
- HQ
- Bilthoven
Aglaia Oncology Funds Questions
Aglaia Oncology Funds's helpline number is +31 30 229 6090
Aglaia Oncology Funds's website is aglaia-biomedical.com
Aglaia Oncology Funds's LinkedIn profile is https://nl.linkedin.com/company/aglaia-biomedical-ventures
Aglaia Oncology Funds has
6 employees.
View email and phone details for 6
employees at Aglaia Oncology Funds.
Aglaia Oncology Funds's industry is
Biotechnology Research
Aglaia Oncology Funds's top competitors are
Inthera Bioscience Ag,
V-Bio Ventures,
Forty51 Ventures,
Curie Capital Bv,
Cristal Therapeutics,
Aglaia Investment Management,
Catalyze Capital,
Myosotis Investments Bv,
Flerie,
Oncode Accelerator.
Aglaia Oncology Funds's support email address is info@aglaia-biomedical.com
Aglaia Oncology Funds's categories are Biotechnology Research
Aglaia Oncology Funds's founding year is 2003
